United States · Series C startup

Who invested in Evergreen Theragnostics

One round we have observed, with the 2 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$26Mraised across 1 round since 2024, from 1 source

Latest round
Series C, $26MApr 2024
Investors
2
See who backed them

The rounds

  1. Apr 2024
    Series C$26M

    Source recorded

Founders and team

From Evergreen Theragnostics's own website and the SEC filings it signed: 3 on the team.

  • Alison TillbrookVP of Human Resources
  • Dipesh PatelGeneral Counsel
  • James CookExecutive Officer, Directori

On the board, as filediEnrico De MariaGerard BerSerge LyashchenkoSharon Roded

Everyone who backed them

Club degli InvestitoriAngel network1round
LIFTTVC firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Evergreen Theragnostics

Who invested in Evergreen Theragnostics?

Evergreen Theragnostics's investors include Club degli Investitori and LIFTT.

How much has Evergreen Theragnostics raised?

Evergreen Theragnostics has raised $26M across 1 round since 2024.

When did Evergreen Theragnostics last raise?

Evergreen Theragnostics's most recent round was a Series C of $26M in Apr 2024.

What was Evergreen Theragnostics's biggest round?

Its most recent round, $26M in Apr 2024, is also its largest on record.

Who backed Evergreen Theragnostics first?

Evergreen Theragnostics's first round on record, in Apr 2024, was backed by Club degli Investitori and LIFTT.

What stage is Evergreen Theragnostics at?

Evergreen Theragnostics's latest named round is a Series C, in Apr 2024.

Where is Evergreen Theragnostics based?

Evergreen Theragnostics is based in the United States.

Companies like Evergreen Theragnostics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.